We need to manage expectations correctly
FDAs Coordinated Enforcement on GLP-1 Promotion & Compounding: Hims & Hers, Eli Lilly, and Novo Nordisk Receive Warning Letters on the Same Day Notes from a Clinical & Regulatory Perspective On 2025/9/9, the FDA issued Warning Letters to Hims & Hers, Eli Lilly, and Novo Nordisk on the same day
And now there is a class of medications that might actually help with both the weight and the inflammation, but the research is still catching up to the excitement
This suggests that gustatory cortex GLP-1R signaling may modulate the perception of palatability, particularly when foods differ in macronutrient composition from familiar diets (Dossat et al., 2023)
Compounded semaglutide and tirzepatide are not FDA-approved, and are used off-label when clinically appropriate
The goal is to recover gently